(HQY) HealthEquity - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US42226A1079
Stock: HSA, FSA, HRA, Investment, Advisory
Total Rating 27
Risk 77
Buy Signal -1.29
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 42.1% |
| Relative Tail Risk | -4.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.71 |
| Alpha | -44.64 |
| Character TTM | |
|---|---|
| Beta | 0.996 |
| Beta Downside | 1.308 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.96% |
| CAGR/Max DD | 0.25 |
Description: HQY HealthEquity January 07, 2026
HealthEquity, Inc. (NASDAQ:HQY) operates a technology-enabled platform that administers health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and related pre-tax benefit programs for U.S. consumers and employers. Its services are delivered through a direct sales force and a partner network that includes health plans, benefits brokers, and retirement-plan record-keepers.
Key recent metrics (FY 2023): revenue reached approximately $1.1 billion, up about 15 % year-over-year; total HSA balances surpassed $15 billion, reflecting a growing employer shift toward high-deductible health plans; and the platform now serves roughly 12 million members. The primary economic drivers are the tax-advantaged nature of HSAs and the broader trend toward consumer-directed health care, while sector dynamics are shaped by regulatory guidance on pre-tax benefit limits and the continued rollout of high-deductible plans.
For a deeper dive into HQY’s valuation metrics and peer comparison, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 191.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 16.41 > 1.0 |
| NWC/Revenue: 29.29% < 20% (prev 29.62%; Δ -0.32% < -1%) |
| CFO/TA 0.12 > 3% & CFO 414.9m > Net Income 191.8m |
| Net Debt (719.0m) to EBITDA (460.8m): 1.56 < 3 |
| Current Ratio: 4.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.0m) vs 12m ago -1.88% < -2% |
| Gross Margin: 61.46% > 18% (prev 0.56%; Δ 6090 % > 0.5%) |
| Asset Turnover: 37.48% > 50% (prev 32.98%; Δ 4.51% > 0%) |
| Interest Coverage Ratio: 5.17 > 6 (EBITDA TTM 460.8m / Interest Expense TTM 59.1m) |
Altman Z'' 1.71
| A: 0.11 (Total Current Assets 498.7m - Total Current Liabilities 120.6m) / Total Assets 3.40b |
| B: 0.06 (Retained Earnings 207.9m / Total Assets 3.40b) |
| C: 0.09 (EBIT TTM 305.6m / Avg Total Assets 3.44b) |
| D: 0.17 (Book Value of Equity 216.8m / Total Liabilities 1.26b) |
| Altman-Z'' Score: 1.71 = BBB |
Beneish M -3.15
| DSRI: 0.93 (Receivables 111.2m/106.7m, Revenue 1.29b/1.15b) |
| GMI: 0.91 (GM 61.46% / 55.93%) |
| AQI: 1.00 (AQ_t 0.84 / AQ_t-1 0.84) |
| SGI: 1.12 (Revenue 1.29b / 1.15b) |
| TATA: -0.07 (NI 191.8m - CFO 414.9m) / TA 3.40b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of HQY shares?
As of February 07, 2026, the stock is trading at USD 79.45 with a total of 1,165,716 shares traded.
Over the past week, the price has changed by -7.26%, over one month by -16.76%, over three months by -14.33% and over the past year by -29.11%.
Over the past week, the price has changed by -7.26%, over one month by -16.76%, over three months by -14.33% and over the past year by -29.11%.
Is HQY a buy, sell or hold?
HealthEquity has received a consensus analysts rating of 4.57.
Therefore, it is recommended to buy HQY.
- StrongBuy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HQY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 119.1 | 49.9% |
| Analysts Target Price | 119.1 | 49.9% |
| ValueRay Target Price | 75.8 | -4.6% |
HQY Fundamental Data Overview February 04, 2026
P/E Trailing = 39.9404
P/E Forward = 19.1571
P/S = 5.8338
P/B = 3.4298
P/EG = 0.7658
Revenue TTM = 1.29b USD
EBIT TTM = 305.6m USD
EBITDA TTM = 460.8m USD
Long Term Debt = 982.1m USD (from longTermDebt, last quarter)
Short Term Debt = 9.93m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 719.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.25b USD (7.53b + Debt 1.03b - CCE 309.3m)
Interest Coverage Ratio = 5.17 (Ebit TTM 305.6m / Interest Expense TTM 59.1m)
EV/FCF = 20.64x (Enterprise Value 8.25b / FCF TTM 399.7m)
FCF Yield = 4.85% (FCF TTM 399.7m / Enterprise Value 8.25b)
FCF Margin = 30.97% (FCF TTM 399.7m / Revenue TTM 1.29b)
Net Margin = 14.86% (Net Income TTM 191.8m / Revenue TTM 1.29b)
Gross Margin = 61.46% ((Revenue TTM 1.29b - Cost of Revenue TTM 497.5m) / Revenue TTM)
Gross Margin QoQ = 62.41% (prev 63.10%)
Tobins Q-Ratio = 2.43 (Enterprise Value 8.25b / Total Assets 3.40b)
Interest Expense / Debt = 1.37% (Interest Expense 14.0m / Debt 1.03b)
Taxrate = 23.46% (15.8m / 67.5m)
NOPAT = 233.9m (EBIT 305.6m * (1 - 23.46%))
Current Ratio = 4.13 (Total Current Assets 498.7m / Total Current Liabilities 120.6m)
Debt / Equity = 0.48 (Debt 1.03b / totalStockholderEquity, last quarter 2.13b)
Debt / EBITDA = 1.56 (Net Debt 719.0m / EBITDA 460.8m)
Debt / FCF = 1.80 (Net Debt 719.0m / FCF TTM 399.7m)
Total Stockholder Equity = 2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.57% (Net Income 191.8m / Total Assets 3.40b)
RoE = 9.01% (Net Income TTM 191.8m / Total Stockholder Equity 2.13b)
RoCE = 9.82% (EBIT 305.6m / Capital Employed (Equity 2.13b + L.T.Debt 982.1m))
RoIC = 7.41% (NOPAT 233.9m / Invested Capital 3.16b)
WACC = 8.56% (E(7.53b)/V(8.56b) * Re(9.59%) + D(1.03b)/V(8.56b) * Rd(1.37%) * (1-Tc(0.23)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
[DCF Debug] Terminal Value 67.70% ; FCFF base≈399.7m ; Y1≈262.4m ; Y5≈119.7m
Fair Price DCF = 16.39 (EV 2.13b - Net Debt 719.0m = Equity 1.41b / Shares 86.2m; r=8.56% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 46.32 | EPS CAGR: -36.19% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.40 | Revenue CAGR: 13.06% | SUE: 0.33 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.14 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=9
EPS next Year (2027-01-31): EPS=4.57 | Chg30d=+0.003 | Revisions Net=+0 | Growth EPS=+15.5% | Growth Revenue=+7.3%
P/E Forward = 19.1571
P/S = 5.8338
P/B = 3.4298
P/EG = 0.7658
Revenue TTM = 1.29b USD
EBIT TTM = 305.6m USD
EBITDA TTM = 460.8m USD
Long Term Debt = 982.1m USD (from longTermDebt, last quarter)
Short Term Debt = 9.93m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 719.0m USD (from netDebt column, last quarter)
Enterprise Value = 8.25b USD (7.53b + Debt 1.03b - CCE 309.3m)
Interest Coverage Ratio = 5.17 (Ebit TTM 305.6m / Interest Expense TTM 59.1m)
EV/FCF = 20.64x (Enterprise Value 8.25b / FCF TTM 399.7m)
FCF Yield = 4.85% (FCF TTM 399.7m / Enterprise Value 8.25b)
FCF Margin = 30.97% (FCF TTM 399.7m / Revenue TTM 1.29b)
Net Margin = 14.86% (Net Income TTM 191.8m / Revenue TTM 1.29b)
Gross Margin = 61.46% ((Revenue TTM 1.29b - Cost of Revenue TTM 497.5m) / Revenue TTM)
Gross Margin QoQ = 62.41% (prev 63.10%)
Tobins Q-Ratio = 2.43 (Enterprise Value 8.25b / Total Assets 3.40b)
Interest Expense / Debt = 1.37% (Interest Expense 14.0m / Debt 1.03b)
Taxrate = 23.46% (15.8m / 67.5m)
NOPAT = 233.9m (EBIT 305.6m * (1 - 23.46%))
Current Ratio = 4.13 (Total Current Assets 498.7m / Total Current Liabilities 120.6m)
Debt / Equity = 0.48 (Debt 1.03b / totalStockholderEquity, last quarter 2.13b)
Debt / EBITDA = 1.56 (Net Debt 719.0m / EBITDA 460.8m)
Debt / FCF = 1.80 (Net Debt 719.0m / FCF TTM 399.7m)
Total Stockholder Equity = 2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.57% (Net Income 191.8m / Total Assets 3.40b)
RoE = 9.01% (Net Income TTM 191.8m / Total Stockholder Equity 2.13b)
RoCE = 9.82% (EBIT 305.6m / Capital Employed (Equity 2.13b + L.T.Debt 982.1m))
RoIC = 7.41% (NOPAT 233.9m / Invested Capital 3.16b)
WACC = 8.56% (E(7.53b)/V(8.56b) * Re(9.59%) + D(1.03b)/V(8.56b) * Rd(1.37%) * (1-Tc(0.23)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
[DCF Debug] Terminal Value 67.70% ; FCFF base≈399.7m ; Y1≈262.4m ; Y5≈119.7m
Fair Price DCF = 16.39 (EV 2.13b - Net Debt 719.0m = Equity 1.41b / Shares 86.2m; r=8.56% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 46.32 | EPS CAGR: -36.19% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.40 | Revenue CAGR: 13.06% | SUE: 0.33 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.14 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=9
EPS next Year (2027-01-31): EPS=4.57 | Chg30d=+0.003 | Revisions Net=+0 | Growth EPS=+15.5% | Growth Revenue=+7.3%